CL2015001652A1 - Compuestos derivados de 4-(bifenil-3-il)-7h-imidazo[4,5-c]piridazina, moduladores de la actividad del receptor gabaa; composicion farmaceutica que los comprende; combinacion que los comprende junto a un segundo agente farmaceuticamente activo; metodo de tratamiento del dolor; y su uso para el tratamiento del dolor. - Google Patents
Compuestos derivados de 4-(bifenil-3-il)-7h-imidazo[4,5-c]piridazina, moduladores de la actividad del receptor gabaa; composicion farmaceutica que los comprende; combinacion que los comprende junto a un segundo agente farmaceuticamente activo; metodo de tratamiento del dolor; y su uso para el tratamiento del dolor.Info
- Publication number
- CL2015001652A1 CL2015001652A1 CL2015001652A CL2015001652A CL2015001652A1 CL 2015001652 A1 CL2015001652 A1 CL 2015001652A1 CL 2015001652 A CL2015001652 A CL 2015001652A CL 2015001652 A CL2015001652 A CL 2015001652A CL 2015001652 A1 CL2015001652 A1 CL 2015001652A1
- Authority
- CL
- Chile
- Prior art keywords
- pain
- treatment
- imidazo
- pyridazine
- modulators
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/04—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/50—Pyridazines; Hydrogenated pyridazines
- A61K31/5025—Pyridazines; Hydrogenated pyridazines ortho- or peri-condensed with heterocyclic ring systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/04—Centrally acting analgesics, e.g. opioids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/08—Antiepileptics; Anticonvulsants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/22—Anxiolytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Neurology (AREA)
- Biomedical Technology (AREA)
- Neurosurgery (AREA)
- Epidemiology (AREA)
- Pain & Pain Management (AREA)
- Rheumatology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Plural Heterocyclic Compounds (AREA)
- Cosmetics (AREA)
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201261737157P | 2012-12-14 | 2012-12-14 |
Publications (1)
Publication Number | Publication Date |
---|---|
CL2015001652A1 true CL2015001652A1 (es) | 2015-08-14 |
Family
ID=49880883
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CL2015001652A CL2015001652A1 (es) | 2012-12-14 | 2015-06-12 | Compuestos derivados de 4-(bifenil-3-il)-7h-imidazo[4,5-c]piridazina, moduladores de la actividad del receptor gabaa; composicion farmaceutica que los comprende; combinacion que los comprende junto a un segundo agente farmaceuticamente activo; metodo de tratamiento del dolor; y su uso para el tratamiento del dolor. |
Country Status (44)
Families Citing this family (13)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2015189744A1 (en) * | 2014-06-12 | 2015-12-17 | Pfizer Limited | Imidazopyridazine derivatives as modulators of the gabaa receptor activity. |
PT3174858T (pt) | 2014-07-31 | 2019-07-23 | Basf Se | Processo para preparar pirazoles |
ES2882543T3 (es) | 2015-05-11 | 2021-12-02 | Basf Se | Proceso para la preparación de 4-amino-piridazinas |
EP3386983A1 (en) * | 2015-12-10 | 2018-10-17 | Pfizer Limited | 4-(biphen-3-yl)-1h-pyrazolo[3,4-c]pyridazine derivatives of formula (i) as gaba receptor modulators for use in the treatment of epilepsy and pain |
WO2018055550A1 (en) * | 2016-09-23 | 2018-03-29 | Novartis Ag | Indazole compounds for use in tendon and/or ligament injuries |
JOP20190053A1 (ar) * | 2016-09-23 | 2019-03-21 | Novartis Ag | مركبات أزا إندازول للاستخدام في إصابات الأوتار و/ أو الرباط |
WO2018082964A1 (en) | 2016-11-04 | 2018-05-11 | Basf Se | Process for the production of pyridazinyl-amides in a one-pot synthesis |
WO2018202494A1 (de) | 2017-05-02 | 2018-11-08 | Bayer Aktiengesellschaft | 2-(het)aryl-substituierte kondensierte heterocyclen-derivate als schädlingsbekämpfungsmittel |
EP3634420A1 (en) * | 2017-06-06 | 2020-04-15 | Urovant Sciences GmbH | Use of vibegron to treat overactive bladder |
WO2019226820A1 (en) * | 2018-05-22 | 2019-11-28 | Neurocycle Therapeutics, Inc. | Gabaa positive allosteric modulator compounds for treatment of itch and/ or dermatitis |
TW202214648A (zh) * | 2019-01-07 | 2022-04-16 | 美商美國禮來大藥廠 | Il-17a抑制劑 |
CN116693555A (zh) * | 2022-02-25 | 2023-09-05 | 上海赛默罗生物科技有限公司 | 咪唑并哒嗪类衍生物、其制备方法、药物组合物和用途 |
CN117069725A (zh) * | 2022-05-10 | 2023-11-17 | 上海赛默罗生物科技有限公司 | 咪唑并哒嗪取代苯环类衍生物、制备方法、药物组合物及用途 |
Family Cites Families (15)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
KR0166088B1 (ko) | 1990-01-23 | 1999-01-15 | . | 수용해도가 증가된 시클로덱스트린 유도체 및 이의 용도 |
US5376645A (en) | 1990-01-23 | 1994-12-27 | University Of Kansas | Derivatives of cyclodextrins exhibiting enhanced aqueous solubility and the use thereof |
GB9518953D0 (en) | 1995-09-15 | 1995-11-15 | Pfizer Ltd | Pharmaceutical formulations |
WO2000035296A1 (en) | 1996-11-27 | 2000-06-22 | Wm. Wrigley Jr. Company | Improved release of medicament active agents from a chewing gum coating |
GB9711643D0 (en) | 1997-06-05 | 1997-07-30 | Janssen Pharmaceutica Nv | Glass thermoplastic systems |
US6365589B1 (en) | 1998-07-02 | 2002-04-02 | Bristol-Myers Squibb Pharma Company | Imidazo-pyridines, -pyridazines, and -triazines as corticotropin releasing factor antagonists |
ES2251518T3 (es) | 2000-11-10 | 2006-05-01 | MERCK SHARP & DOHME LTD. | Derivados de imidazo-triazina como ligandos para receptores gaba. |
GB0117277D0 (en) | 2001-07-16 | 2001-09-05 | Merck Sharp & Dohme | Therapeutic agents |
CA2555263A1 (en) * | 2004-02-12 | 2005-09-01 | Neurogen Corporation | Imidazo-pyridazines, triazolo-pyridazines and related benzodiazepine receptor ligands |
US20080132510A1 (en) | 2005-01-21 | 2008-06-05 | Bingsong Han | Imidazolylmethyl and Pyrazolylmethyl Heteroaryl Derivatives |
EP1845098A1 (en) * | 2006-03-29 | 2007-10-17 | Ferrer Internacional, S.A. | Imidazo[1,2-b]pyridazines, their processes of preparation and their use as GABA receptor ligands |
EP1995241B1 (en) | 2007-03-23 | 2010-03-17 | ICAgen, Inc. | Inhibitors of ion channels |
MA32965B1 (fr) | 2009-01-12 | 2012-01-02 | Pfizer Ltd | Derives de sulfonamides |
MX2012004990A (es) * | 2009-10-30 | 2012-06-12 | Janssen Pharmaceutica Nv | Deribados de imidazo [1,2-b] pirimideazina y su uso como inhibidores de la enzima fosfodiesterasa 10. |
ES2526675T3 (es) * | 2010-07-09 | 2015-01-14 | Pfizer Limited | N-sulfonilbenzamidas como inhibidores de los canales de sodio dependientes de voltaje |
-
2013
- 2013-04-12 UA UAA201504677A patent/UA112028C2/uk unknown
- 2013-12-04 MD MDA20150051A patent/MD4651B1/ro not_active IP Right Cessation
- 2013-12-04 RS RS20160986A patent/RS55307B1/sr unknown
- 2013-12-04 MX MX2015007598A patent/MX366023B/es active IP Right Grant
- 2013-12-04 EP EP13812165.2A patent/EP2938615B1/en active Active
- 2013-12-04 WO PCT/IB2013/060631 patent/WO2014091368A1/en active Application Filing
- 2013-12-04 HU HUE13812165A patent/HUE032400T2/hu unknown
- 2013-12-04 CA CA2892174A patent/CA2892174C/en active Active
- 2013-12-04 GE GEAP201313849A patent/GEP201706710B/en unknown
- 2013-12-04 PE PE2015000912A patent/PE20151163A1/es not_active Application Discontinuation
- 2013-12-04 CU CUP2015000058A patent/CU24338B1/es unknown
- 2013-12-04 ES ES13812165.2T patent/ES2608640T3/es active Active
- 2013-12-04 PT PT138121652T patent/PT2938615T/pt unknown
- 2013-12-04 SI SI201330382T patent/SI2938615T1/sl unknown
- 2013-12-04 SG SG11201503735YA patent/SG11201503735YA/en unknown
- 2013-12-04 EA EA201590761A patent/EA025635B1/ru not_active IP Right Cessation
- 2013-12-04 KR KR1020157017073A patent/KR101746314B1/ko active IP Right Grant
- 2013-12-04 AP AP2015008526A patent/AP2015008526A0/xx unknown
- 2013-12-04 DK DK13812165.2T patent/DK2938615T3/da active
- 2013-12-04 ME MEP-2016-258A patent/ME02566B/me unknown
- 2013-12-04 AU AU2013356894A patent/AU2013356894B2/en active Active
- 2013-12-04 LT LTEP13812165.2T patent/LT2938615T/lt unknown
- 2013-12-04 MA MA38112A patent/MA38112B1/fr unknown
- 2013-12-04 PL PL13812165T patent/PL2938615T3/pl unknown
- 2013-12-04 JP JP2015547219A patent/JP5869740B2/ja active Active
- 2013-12-04 CN CN201380065006.0A patent/CN104837843B/zh active Active
- 2013-12-04 BR BR112015014097-1A patent/BR112015014097B1/pt active IP Right Grant
- 2013-12-11 TW TW102145600A patent/TWI478926B/zh active
- 2013-12-12 UY UY35185A patent/UY35185A/es unknown
- 2013-12-12 US US14/103,960 patent/US8952008B2/en active Active
- 2013-12-12 AR ARP130104648A patent/AR093937A1/es unknown
-
2014
- 2014-12-19 US US14/576,796 patent/US20150105396A1/en not_active Abandoned
-
2015
- 2015-05-14 CR CR20150254A patent/CR20150254A/es unknown
- 2015-05-29 US US14/725,234 patent/US20150259352A1/en not_active Abandoned
- 2015-06-04 IL IL239243A patent/IL239243A0/en active IP Right Grant
- 2015-06-05 PH PH12015501293A patent/PH12015501293A1/en unknown
- 2015-06-09 TN TNP2015000261A patent/TN2015000261A1/fr unknown
- 2015-06-11 ZA ZA2015/04226A patent/ZA201504226B/en unknown
- 2015-06-11 NI NI201500081A patent/NI201500081A/es unknown
- 2015-06-12 CL CL2015001652A patent/CL2015001652A1/es unknown
- 2015-06-12 DO DO2015000147A patent/DOP2015000147A/es unknown
- 2015-07-11 EC ECIEPI201529822A patent/ECSP15029822A/es unknown
- 2015-08-04 GT GT201500159A patent/GT201500159A/es unknown
- 2015-10-28 HK HK15110627.3A patent/HK1209743A1/zh unknown
-
2016
- 2016-11-22 HR HRP20161559TT patent/HRP20161559T1/hr unknown
- 2016-12-05 CY CY20161101251T patent/CY1118568T1/el unknown
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CL2015001652A1 (es) | Compuestos derivados de 4-(bifenil-3-il)-7h-imidazo[4,5-c]piridazina, moduladores de la actividad del receptor gabaa; composicion farmaceutica que los comprende; combinacion que los comprende junto a un segundo agente farmaceuticamente activo; metodo de tratamiento del dolor; y su uso para el tratamiento del dolor. | |
CR20140365A (es) | Compuestos de carbamato y preparación y uso de los mismos | |
BR112014000284A8 (pt) | composição fotoprotetora, uso de baicalina, agente multiconstituinte para a fotoproteção de matérias queratínicas humanas, usos de uma composição e usos de um agente multiconstituinte | |
CL2014002757A1 (es) | Compuestos derivados de benzamida para inhibir la actividad de abl1, abl2 y bcr-abl1, composicion farmaceutica; y uso en el tratamiento del cancer. | |
CR20140117A (es) | Composiciones parasiticidas que comprenden un agente activo de isoxazolina, sus métodos y usos | |
CL2014000956A1 (es) | Compuestos derivados de (4-fenilimidazol-2-il)etilamina, como moduladores de canal de sodio; composicion farmaceutica que los comprende; y su uso en el tratamiento del dolor. | |
CL2015000295A1 (es) | Compuestos derivados de alquilpirimidina; composicion farmaceutica que los comprende; uso para el tratamiento de infecciones víricas y otras enfermedades. | |
WO2014205389A8 (en) | Nuclear transport modulators and uses thereof | |
CL2015003801A1 (es) | Formulaciones de anticuerpos y metodos | |
BR112015003397A2 (pt) | composto, composição farmacêutica, uso do composto e método para tratar uma doença ou condição mediada por rorgammat em um paciente. | |
BR112015018092A2 (pt) | moduladores de receptor de nmda de espiro-lactama e usos dos mesmos | |
BR112015002541A2 (pt) | composto, composição farmacêutica, uso de um composto, e, método para tratamento de hcv em um paciente. | |
BR112015003332A2 (pt) | composto, composição farmacêutica, uso do composto e método para tratar uma doença ou condição mediada por rorgammat em um paciente | |
PE20151416A1 (es) | Moduladores de receptores nmda de espiro-lactama y sus usos | |
BR112015003398A2 (pt) | composto, composição farmacêutica, uso do composto e método para tratar uma doença ou condição mediada por rorgammat em um paciente | |
BR112015018094A2 (pt) | moduladores de receptor nmda de espiro-lactama e usos dos mesmos | |
WO2013170068A3 (en) | Nuclear transport modulators and uses thereof | |
CL2015003072A1 (es) | Formulaciones de liberación prolongada de colchicina y métodos de uso de las mismas. | |
BR112012022797A2 (pt) | composição farmacêutica resistente a álcool, e, método para tratar uma doença com uma formulação de agente ativo resistente a álcool | |
CL2019000245A1 (es) | Moduladores nmda espiro-lactam y métodos de uso de los mismos. | |
BR112015018089A2 (pt) | moduladores de receptor de nmda de espiro-lactama e usos dos mesmos | |
BR112015018095A2 (pt) | moduladores de receptor nmda de espiro-lactama e usos dos mesmos | |
CL2015000891A1 (es) | Compuestos derivados de fenil-etinilo, moduladores de la actividad del receptor mglur5; proceso de preparacion; composicion farmaceutica; y uso en el tratamiento de la ansiedad, dolor, depresion,entre otras. | |
CL2015001085A1 (es) | Formulacion de liberación prolongada que comprende oprozomib y ademas uno o mas polimeros farmaceuticamente aceptables; metodo de preparacion de la formulacion; metodo para tratar cancer. | |
CO6640216A2 (es) | Composiciones farmacéuticas que comprenden hidromorfona y naloxona |